Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.55 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.55 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.52 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL91058 | 0.88 | RXFP1 (0.46) | SLC29A1ADORA1ADORA3P2RX3P2RX2 | |
| SCHEMBL11267406 | 0.87 | P2RX3 (0.65) | SLC29A1ADORA1ADORA3P2RX3P2RX2 | |
| SCHEMBL14853952 | 0.84 | SLC29A1 (0.64) | SLC29A1ADORA1ADORA3ADORA2A | |
| SCHEMBL14946385 | 0.84 | SLC29A1 (0.64) | SLC29A1ADORA1ADORA3ADORA2A | |
| SCHEMBL14946384 | 0.83 | P2RX3 (0.58) | SLC29A1ADORA1ADORA3P2RX3P2RX2 | |
| SCHEMBL14929351 | 0.83 | P2RX3 (0.58) | SLC29A1ADORA1ADORA3P2RX3P2RX2 | |
| SCHEMBL2472334 | 0.81 | SLC29A1 (0.58) | SLC29A1ADORA1ADORA3P2RX3P2RX2 | |
| SCHEMBL14929323 | 0.80 | P2RX3 (0.73) | P2RX3P2RX2 | |
| SCHEMBL14946398 | 0.80 | P2RX3 (0.73) | P2RX3P2RX2 | |
| Imidazole SCHEMBL11397091 | 0.80 | P2RX3 (0.56) | SLC29A1ADORA1ADORA3P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129106-B2 | Sequence-specific detection of methylation in biomolecules | Max-Planck-Geselischaft zur Forderung der Wissenschaften E.V. (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20110165564-A1 | SEQUENCE-SPECIFIC DETECTION OF METHYLATION IN BIOMOLECULES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165564-A1 | SEQUENCE-SPECIFIC DETECTION OF METHYLATION IN BIOMOLECULES | DNMT1, MAT2B, AHCY | SLC29A1 804/4885ADORA1 1194/4885ADORA3 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.